Renaissance Capital logo

SYRE News

US IPO Weekly Recap: Roadshows begin on three significant IPOs

AGLE

Just one week old, the 2Q has already seen one pricing, three launches, three initial filings and significant filings updates. This represents the most IPO-related activity since early in the 1Q. A familiar move from the biotech playbook ...read more

Cancer biotech Aeglea BioTherapeutics slashes valuation and prices IPO at $10

Spyre Therapeutics (Aeglea BioTherapeutics) logo

Aeglea BioTherapeutics, which is developing enzymes for rare genetic metabolic diseases and tumors, raised $50 million by offering 5 million shares at $10. It had originally planned to raise $60 million by offering 3.5 million shares at a range of $16 to $18....read more

Week ahead: Small-cap biotech IPO kicks-off Q2

Spyre Therapeutics (Aeglea BioTherapeutics) logo

•Another small-cap biotech is set to kick off Q2 pricings •Timing of the IPO window reopening is still uncertain, but the pipeline remains robust First IPO of the second quarter ...read more

Metabolic biotech Aeglea BioTherapeutics sets terms for $60 million IPO

Spyre Therapeutics (Aeglea BioTherapeutics) logo

Aeglea BioTherapeutics, which is developing enzymes for rare genetic metabolic diseases and tumors, announced terms for its IPO on Monday. The Austin, TX-based company plans to raise $60 million by offering 3.5 million shares at a price range of $16 to $18....read more